Fundz

Ocular Therapeutix, Inc reported raising $37.5 Million in an initial SEC Form D filing, from an offering of $37.5 Million

PUBLIC · OCULMar 18, 2019

Amount Raised

$37.5 Million

$37.5 Million sold, per SEC Form D (first sale Mar 18, 2019)

Round Type

Venture

BedfordBiotechnologyHealth CareTherapeuticsPharmaceutical

Quick answer

Ocular Therapeutix raised $37.5 Million in a funding round, dated March 18, 2019. Ocular Therapeutix is based in Bedford, Massachusetts, United States.

How much did Ocular Therapeutix raise?
Ocular Therapeutix raised $37.5 Million in a funding round on March 18, 2019.
What does Ocular Therapeutix do?
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience across drug development, treatment, and outcomes.
Where is Ocular Therapeutix based and how big is it?
Ocular Therapeutix is based in Bedford, Massachusetts, United States.

Source: Fundz verified event record.

Who else raised in Therapeutics and Pharmaceutical around the same time

Companies in the same sectors as Ocular Therapeutix that raised within 45 days of this round, from Fundz verified event records.

Who to call at Ocular Therapeutix, and when

A new round usually means Ocular Therapeutix is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Ocular Therapeutix raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Ocular Therapeutix, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Ocular Therapeutix. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Ocular Therapeutix

Location

Bedford, Massachusetts, United States

About

Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience across drug development, treatment, and outcomes. AXPAXLI™ (also known as OTX-TKI), an investigational axitinib hydrogel administered by intravitreal injection, is Ocular’s leading investigational candidate for retinal disease, based on its proprietary ELUTYX™ technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and has potential applications across other retinal diseases such as non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME).

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Ocular Therapeutix raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Ocular Therapeutix's next move

See what Strategic adds

Ocular Therapeutix raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.